Bicycle and CRUK to launch first clinical trial of bicyclic peptide for use in treating tumours

Bicycle Therapeutics and Cancer Research UK have commenced the first clinical study to assess a bicyclic peptide to evaluate its potential in patients with advanced solid tumours. The first patient has now been dosed in a Phase I/IIa trial with BT1718, a first-in-class Bicycle Toxin Conjugate that targets Membrane Type 1 Matrix Metalloproteinase, which is

Continue Reading

Oxford based Nanopore’s technology achieves genome sequencing landmark

New technique for gene sequencing has produced the most complete human genome ever assembled with a single technology, the nanapore, developed by UK company Oxford Nanopore Technologies. The miniaturised device has proven its speed and accuracy through the company’s collaboration with an international consortium of researchers and sets the firm up for a major commercial

Continue Reading

New cancer blood test breakthrough

Scientists from Johns Hopkins University have taken a step towards one of the biggest goals in medicine, a universal blood test for cancer. The researchers have trialled a method that can detect up to eight common forms of the disease. The scientists envision the research to be developed into an annual test designed to catch

Continue Reading

CRUK and Institute of Cancer Research, London collaborate with Merck in new drug discovery alliance

Cancer Research UK’s Commercial Partnerships Team and The Institute of Cancer Research, announced a multi-project collaboration and licensing deal with Merck, a leading science and technology company, to discover and develop new anticancer drugs. “It is an exciting example of how successful academic networks and the scale of industry can combine to advance scientific and

Continue Reading

Imperial College London leads newly launched hub for manufacturing vaccines

A £10 million Future Vaccine Manufacturing Hub led by Imperial College London has been officially launched. The Hub, which involves various research partners, will be led by Professor Robin Shattock from Imperial’s Department of Medicine and involves scientists across Departments of Chemical Engineering and Life Sciences. The researchers at the Hub aim to improve the

Continue Reading

Method using microbubbles for delivery drugs could “revolutionise” future of drug discovery

Ground-breaking method of delivering lifesaving drugs using microbubbles is moving closer to being used in patients, due to a new research project between Medicines Discovery Catapult and the University of Leeds at Medicines Discovery Catapult’s laboratories in Alderley Park. Due to toxic side effects, many life-saving and life-improving drugs cannot be used to treat patients.

Continue Reading